Half year report on Adocia’s liquidity agreement with Kepler Capital Markets

Lyon, France, July 7, 2015 – Under the liquidity agreement entrusted by Adocia to Kepler Capital Markets, the following resources were listed on the liquidity account as at June 30, 2015:

- 2,257 shares of Adocia and
- 83,378.96 euros in cash.

At the last half year report dated December 31, 2014, the following resources were listed on the liquidity account:

- 2,323 shares of Adocia and
- 778,747.18 euros in cash.

It is reminded that, on February 10, 2015, Adocia decided to proceed to a partial withdrawal of the funds allocated to this agreement for an amount of EUR 700,000.

About Adocia

To be a global leader in the innovative delivery of insulins and therapeutic proteins

Adocia is a clinical stage biotechnology company that specializes in the development of innovative formulations of already approved therapeutic proteins. It has a particularly strong expertise in the field of insulins. Adocia’s proprietary BioChaperone® technological platform is designed to enhance the effectiveness and safety of therapeutic proteins and their ease of use for patients.

In December 2014, Adocia signed a partnership with Eli Lilly for the development and commercialization of its new formulation of insulin lispro, BioChaperone Lispro, previously tested successfully in two phase Ib/IIa studies.

Adocia will continue to develop its fast-acting human insulin formulation internally. Two clinical studies are planned over 2015, a post-meal glucose control study with HinsBet U100 and a PK/PD study with HinsBet U500. Adocia is also actively continuing the development of its BioChaperone Combo, a unique combination of insulin Glargine, the gold-standard of basal insulin and insulin lispro, a fast-acting insulin analog. Two Phase IIa clinical studies are scheduled for the third quarter 2015, one which is a glycemic control after a standardized meal with type 1 diabetic patients, the other clinical study is about pharmacodynamics in euglycemic clamp with type 2 diabetic patients. A dose-response clinical study in type 1 diabetic patients is also scheduled for the fourth quarter of 2015.
In addition, Adocia launched a phase III clinical study in India on its product based on PDGF-BB for treatment of the diabetic foot ulcer (BioChaperone PDGF-BB) in August 2014.

Adocia has extended its activities to the formulation of monoclonal antibodies, which are gold-standard biologics for the treatment of various chronic pathologies (cancer, inflammation, etc.). Adocia is engaged in collaborative programs with two major pharmaceutical companies in this field.

**Fighting cancer with targeted treatments**

DriveIn® is a nanotechnology which is intended to significantly improve delivery of active compounds into cancer cells. This new proprietary platform constitutes an exceptional opportunity to enter the oncology market by improving the efficacy of both already approved treatments and novel proprietary molecules.

« **Innovative medicine for everyone, everywhere** »

Adocia’s therapeutic innovations aim to provide solutions in a profoundly changing global pharmaceutical and economic context, characterized by (i) an increased prevalence and impact of the targeted pathologies, (ii) a growing and ageing population, (iii) a need to control public health expenditures and (iv) an increasing demand from emerging countries.

Adocia is listed on the regulated market of Euronext in Paris (ISIN: FR0011184241; Reuters/Bloomberg ticker: ADOC, ADOC.PA, ADOC.FP) and is included in the Next Biotech, Tech 40 and SBF 120 indexes.

American Depositary Receipts representing Adocia common stock are traded on the US OTC market under the ticker symbol ADOCY.

For more information, visit: [www.adocia.com](http://www.adocia.com)

---

For more information please contact:

<table>
<thead>
<tr>
<th>Adocia</th>
<th>Adocia Press Relations</th>
</tr>
</thead>
<tbody>
<tr>
<td>Gérard Soula</td>
<td>ALIZE RP</td>
</tr>
<tr>
<td>Chairman and CEO of Adocia</td>
<td>Caroline Carmagnol</td>
</tr>
<tr>
<td><a href="mailto:contactinvestisseurs@adocia.com">contactinvestisseurs@adocia.com</a></td>
<td><a href="mailto:caroline@alizerp.com">caroline@alizerp.com</a></td>
</tr>
<tr>
<td>Tel.: +33 4 72 610 610</td>
<td><a href="mailto:adocia@alizerp.com">adocia@alizerp.com</a></td>
</tr>
<tr>
<td></td>
<td>Tel.: + 33 1 44 54 36 61</td>
</tr>
</tbody>
</table>